Tufts University

Harvard College

Wyeth

Children's Medical Center Corporation

Council of Scientific and Industrial Research

The Brigham and Women's Hospital, Inc.

Ensemble Therapeutics Corporation

Jinbo Lee

Philip G Haydon

David D Ginty

Lauren L Orefice

Zhao-Kui Wan

Steve Yikkai Tam

Stephen Moss

Jinghui Dong

Raquel Revilla-Sanchez

Douglas Wilson

David V Erbe

Michael J Smith

Kenneth W Foreman

Eva Deanna Binnun

Weixin Xu

Ralph Mazitschek

Clifford J Woolf

Wei Li

Eddine Saiah

Anjana Rao

Bruce Follows

Tarek Suhayl Mansour

Alexei Degterev

Lihren Chen

Yan-Ling Zhang

John C McKew

Stephen Paul Hale

Julian F Bond

Jason Shaoyun Xiang

Bruce P Bean

Chepuri Venkata Ramana

David P Roberson

Diane Marie Joseph-McCarthy

Benjamin A Seigal

Malcolm Whitman

Abigail Sloan Devlin

Jianchang Li

Snehal N Chaudhari

Huan-Qiu Li

Eric Garland Sheu

David A Harris

Nicholas K Terrett

Steven J Kirincich

Tracy Keller

Yadagiri Kommagalla

Timothy F Briggs

Frank G Favaloro, Jr

Wei-Chuan Sun

Sooyeon Jo

Sebastien Talbot

Jun-Jun Wu

Yuchuan Wu

Vipin Suri

Mark S Sundrud

Daniel Wang

Manus Ipek

Alessandro Fabio Moretto

Mark Sundrud

The compositions and methods provided herein are related, in part, to the discovery of cholic acid 7-sulfate as a treatment for diabetes. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to a subject a compound of Formulae (I)-(XVII).

Synthetic derivatives of cholic acid 7-sulfate and uses thereof

The present invention features novel peripherally-restricted isoguvacine analogs with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome.

Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment

The present invention features novel peripherally-restricted non-benzodiazipene analogs with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome, or for treating touch over-reactivity, pain, or mechanical allodynia.

The present invention provides novel peripherally-restricted benzodiazepines with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome.

This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs for treating various disorders including, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma, and inflammatory conditions, e.g., psoriasis and rheumatoid arthritis.

Uridine diphosphate derivatives, prodrugs, compositions and uses thereof

This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of PYreceptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma and inflammatory conditions.

Uridine nucleoside derivatives, compositions and methods of use

This disclosure relates to uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of PYreceptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease) and traumatic CNS injury, as well as pain.

Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders

The invention provides compounds, compositions, methods, and kits for the treatment of pain, itch, and neurogenic inflammation.

Charged ion channel blockers and methods for use

This disclosure relates to prodrugs of uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs or compositions in treating disorders that are responsive to ligands, such as agonists, of PYreceptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma, and inflammatory conditions.

Uridine diphosphate derivatives, prodrugs, compositions and methods for treating neurodegenerative disorders

Provided are certain 1,2,3-triazole and 1,2,3-triazole dimer analogs of DM-PIT-1 which are second-generation selective non-phosphoinositide small molecule inhibitors of phosphatidylinositol-3,4,5-trisphosphate (PIP3), including 1,2,3-triazoles represented by formula (I) where:

Small molecule inhibitors of PI3-kinase signaling

Growing community of inventors

Andover, MA, United States of America

Jinbo Lee